Nilutamide
http://dbpedia.org/resource/Nilutamide an entity of type: Thing
نيلوتاميد (بالإنجليزية: Nilutamide) هو دواء يُستعمل في علاج:
* سرطانة الخلية المغزلية
* سرطان البروستاتا (منذ 18 سبتمبر 1996)
rdf:langString
Nilutamide è un farmaco orale antiandrogeno utilizzato principalmente per trattare il cancro alla prostata. Il nilutamide blocca i recettori per gli androgeni, prevenendo così l'iterazione con il testosterone.
rdf:langString
Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women. It is taken by mouth. It is on the World Health Organization's List of Essential Medicines.
rdf:langString
rdf:langString
Nilutamide
rdf:langString
نيلوتاميد
rdf:langString
Nilutamide
xsd:integer
3374583
xsd:integer
1121639858
rdf:langString
BB02
rdf:langString
L02
rdf:langString
Good
xsd:integer
12
xsd:integer
63612
xsd:integer
7573
xsd:integer
1274
xsd:integer
4337
rdf:langString
DB00665
<second>
201600.0
<second>
-313200.0
rdf:langString
Feces: <10%
rdf:langString
Urine: 62%
xsd:integer
3
xsd:integer
10
rdf:langString
Nilutamide molecule ball.png
xsd:integer
55
rdf:langString
D00965
rdf:langString
Rx-only
rdf:langString
a697044
xsd:integer
149
rdf:langString
Liver
xsd:integer
3
xsd:integer
4
rdf:langString
C
xsd:integer
4493
rdf:langString
CC1C
xsd:integer
1
rdf:langString
XWXYUMMDTVBTOU-UHFFFAOYSA-N
rdf:langString
RU-23908
rdf:langString
Nilandron, Anandron
xsd:integer
51
xsd:integer
462261036
rdf:langString
changed
xsd:integer
225
rdf:langString
نيلوتاميد (بالإنجليزية: Nilutamide) هو دواء يُستعمل في علاج:
* سرطانة الخلية المغزلية
* سرطان البروستاتا (منذ 18 سبتمبر 1996)
rdf:langString
Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women. It is taken by mouth. Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes. Nausea, vomiting, visual disturbances, alcohol intolerance, elevated liver enzymes, and lung disease can occur in both sexes. Rarely, nilutamide can cause respiratory failure and liver damage. These unfavorable side effects, along with a number of associated cases of death, have limited the use of nilutamide. Nilutamide acts as a selective antagonist of the androgen receptor (AR), preventing the effects of androgens like testosterone and dihydrotestosterone (DHT) in the body. Because most prostate cancer cells rely on these hormones for growth and survival, nilutamide can slow the progression of prostate cancer and extend life in men with the disease. Nilutamide was discovered in 1977 and was first introduced for medical use in 1987. It became available in the United States in 1996. The drug has largely been replaced by newer and improved NSAAs, namely bicalutamide and enzalutamide, due to their better efficacy, tolerability, and safety, and is now rarely used. It is on the World Health Organization's List of Essential Medicines.
rdf:langString
Nilutamide è un farmaco orale antiandrogeno utilizzato principalmente per trattare il cancro alla prostata. Il nilutamide blocca i recettori per gli androgeni, prevenendo così l'iterazione con il testosterone.
xsd:integer
2864
rdf:langString
At least 5, some active
rdf:langString
nye-LOO-tah-mide
xsd:integer
80
xsd:nonNegativeInteger
50836
rdf:langString
Nilandron, Anandron
xsd:string
63612-50-0
xsd:string
7573
xsd:string
1274
xsd:string
DB00665
xsd:string
51G6I8B902
xsd:string
D00965
xsd:string
a697044
xsd:string
4493